IL126696A0 - Azetidinone derivatives for the treatment of atherosclerosis - Google Patents
Azetidinone derivatives for the treatment of atherosclerosisInfo
- Publication number
- IL126696A0 IL126696A0 IL12669697A IL12669697A IL126696A0 IL 126696 A0 IL126696 A0 IL 126696A0 IL 12669697 A IL12669697 A IL 12669697A IL 12669697 A IL12669697 A IL 12669697A IL 126696 A0 IL126696 A0 IL 126696A0
- Authority
- IL
- Israel
- Prior art keywords
- atherosclerosis
- treatment
- azetidinone derivatives
- azetidinone
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
- C07D205/09—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9608646.7A GB9608646D0 (en) | 1996-04-26 | 1996-04-26 | Novel compounds |
GBGB9623756.5A GB9623756D0 (en) | 1996-11-15 | 1996-11-15 | Novel compounds |
GBGB9625121.0A GB9625121D0 (en) | 1996-12-03 | 1996-12-03 | Novel compounds |
PCT/EP1997/001898 WO1997041098A1 (en) | 1996-04-26 | 1997-04-15 | Azetidinone derivatives for the treatment of atherosclerosis |
Publications (1)
Publication Number | Publication Date |
---|---|
IL126696A0 true IL126696A0 (en) | 1999-08-17 |
Family
ID=27268259
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL12669697A IL126696A0 (en) | 1996-04-26 | 1997-04-15 | Azetidinone derivatives for the treatment of atherosclerosis |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP0915843A1 (no) |
JP (1) | JP2000509049A (no) |
AR (1) | AR006833A1 (no) |
AU (1) | AU2698697A (no) |
BR (1) | BR9709196A (no) |
CA (1) | CA2252696A1 (no) |
CZ (1) | CZ341098A3 (no) |
HU (1) | HUP9901359A3 (no) |
ID (1) | ID16660A (no) |
IL (1) | IL126696A0 (no) |
MA (1) | MA26426A1 (no) |
NO (1) | NO984939L (no) |
NZ (1) | NZ332476A (no) |
PE (1) | PE64398A1 (no) |
PL (1) | PL329530A1 (no) |
TR (1) | TR199802160T2 (no) |
WO (1) | WO1997041098A1 (no) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1686119B1 (en) | 2000-02-16 | 2009-07-29 | Smithkline Beecham Plc | Pyrimidine-5-one derivatives as LDL-PLA2 inhibitors |
CN1275949C (zh) | 2001-03-28 | 2006-09-20 | 先灵公司 | 2-吖丁啶酮中间体化合物的对映体选择性合成 |
JP2004532868A (ja) * | 2001-05-25 | 2004-10-28 | シェーリング コーポレイション | アルツハイマー病の処置におけるアゼチジノン置換誘導体の使用 |
AU2008251467B2 (en) | 2007-05-11 | 2014-07-31 | The Trustees Of The University Of Pennsylvania | Methods of treatment of skin ulcers |
US8962633B2 (en) | 2007-05-11 | 2015-02-24 | Thomas Jefferson University | Methods of treatment and prevention of metabolic bone diseases and disorders |
KR101690390B1 (ko) | 2007-05-11 | 2016-12-27 | 토마스 제퍼슨 유니버시티 | 신경변성 질환 및 장애의 치료 및 예방 방법 |
CA2820408C (en) | 2010-12-06 | 2018-03-06 | Glaxo Group Limited | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by lp-pla2 |
EP2651403B1 (en) | 2010-12-17 | 2020-12-02 | Glaxo Group Limited | Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases |
WO2013000267A1 (zh) | 2011-06-27 | 2013-01-03 | 中国科学院上海药物研究所 | 唑类杂环化合物、其制备方法、药物组合物和用途 |
KR20140059203A (ko) | 2011-07-27 | 2014-05-15 | 글락소 그룹 리미티드 | 2,3-디히드로이미다조[1,2-c]피리미딘-5(1h)-온 화합물의 lp-pla2 억제제로서의 용도 |
EP2736908A1 (en) | 2011-07-27 | 2014-06-04 | Glaxo Group Limited | Bicyclic pyrimidone compounds |
KR20150111356A (ko) | 2013-01-25 | 2015-10-05 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 화합물 |
MX2015009633A (es) | 2013-01-25 | 2015-11-30 | Glaxosmithkline Ip Dev Ltd | Inhibidores de fosfolipasa a2 asociada con lipoproteinas basados en 2,3-dihidroimidazol[1,2-c] pirimidin-5(1h)-ona. |
AU2014210260B2 (en) | 2013-01-25 | 2016-08-04 | Glaxosmithkline Intellectual Property Development Limited | Bicyclic pyrimidone compounds as inhibitors of Lp-PLA2 |
WO2016012917A1 (en) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
WO2016012916A1 (en) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
JP2023500710A (ja) | 2019-11-09 | 2023-01-10 | シャンハイ エスアイエムアール バイオテクノロジー カンパニー リミテッド | 三環式ジヒドロイミダゾピリミドン誘導体、その調製方法、その医薬組成物及び使用 |
CN115304620A (zh) | 2021-05-07 | 2022-11-08 | 上海赛默罗生物科技有限公司 | 嘧啶酮衍生物、其制备方法、药物组合物和用途 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4680391A (en) * | 1983-12-01 | 1987-07-14 | Merck & Co., Inc. | Substituted azetidinones as anti-inflammatory and antidegenerative agents |
IL89835A0 (en) * | 1988-04-11 | 1989-12-15 | Merck & Co Inc | Substituted azetidinones,their preparation and pharmaceutical compositions containing them |
IL99658A0 (en) * | 1990-10-15 | 1992-08-18 | Merck & Co Inc | Substituted azetidinones and pharmaceutical compositions containing them |
WO1993000332A1 (en) * | 1991-06-25 | 1993-01-07 | Merck & Co., Inc. | Substituted azetidinones as anti-inflammatory and antidegenerative agents |
CZ14294A3 (en) * | 1991-07-23 | 1994-07-13 | Schering Corp | Substituted beta-lactam compounds usable as hypocholesterol pharmaceutical preparations and process for preparing thereof |
MY128261A (en) * | 1992-10-27 | 2007-01-31 | Merck Sharp & Dohme | New substituted azetidinones as anti-inflammatory and antidegenerative agents |
WO1994013636A1 (en) * | 1992-12-17 | 1994-06-23 | Merck & Co., Inc. | New substituted azetidinones as anti-inflammatory and antidegenerative agents |
US5981252A (en) * | 1993-06-25 | 1999-11-09 | Smithkline Beecham | Lipoprotein associated phospholipase A2, inhibitors thereof and use of the same in diagnosis and therapy |
JP3613398B2 (ja) * | 1993-10-06 | 2005-01-26 | イコス コーポレイション | 血小板活性化因子アセチルヒドロラーゼ |
GB9421816D0 (en) * | 1994-10-29 | 1994-12-14 | Smithkline Beecham Plc | Novel compounds |
AP9701007A0 (en) * | 1994-12-22 | 1997-07-31 | Smithkline Beecham Plc | Substituted azetidin-2-ones for treatment of atherosclerosis. |
AU5014496A (en) * | 1995-03-23 | 1996-10-08 | Japan Tobacco Inc. | Diphenylmethyl-azetidinone compounds and elastase inhibitor |
TR199701762T1 (xx) * | 1995-07-01 | 1998-05-21 | Smithkline Beecham P.L.C. | Damar t�kanmas� tedavisi i�in azetidinon t�revleri. |
JP2000505063A (ja) * | 1995-12-08 | 2000-04-25 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | アテローム性動脈硬化症の治療のためのアゼチジノン化合物 |
-
1997
- 1997-04-15 BR BR9709196A patent/BR9709196A/pt not_active Application Discontinuation
- 1997-04-15 CZ CZ983410A patent/CZ341098A3/cs unknown
- 1997-04-15 NZ NZ332476A patent/NZ332476A/en unknown
- 1997-04-15 IL IL12669697A patent/IL126696A0/xx unknown
- 1997-04-15 EP EP97920699A patent/EP0915843A1/en not_active Withdrawn
- 1997-04-15 PL PL97329530A patent/PL329530A1/xx unknown
- 1997-04-15 CA CA002252696A patent/CA2252696A1/en not_active Abandoned
- 1997-04-15 TR TR1998/02160T patent/TR199802160T2/xx unknown
- 1997-04-15 HU HU9901359A patent/HUP9901359A3/hu unknown
- 1997-04-15 AU AU26986/97A patent/AU2698697A/en not_active Abandoned
- 1997-04-15 JP JP9538507A patent/JP2000509049A/ja active Pending
- 1997-04-15 WO PCT/EP1997/001898 patent/WO1997041098A1/en not_active Application Discontinuation
- 1997-04-24 MA MA24565A patent/MA26426A1/fr unknown
- 1997-04-24 AR ARP970101682A patent/AR006833A1/es unknown
- 1997-04-24 PE PE1997000311A patent/PE64398A1/es not_active Application Discontinuation
- 1997-04-25 ID IDP971394A patent/ID16660A/id unknown
-
1998
- 1998-10-23 NO NO984939A patent/NO984939L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
PE64398A1 (es) | 1999-01-06 |
BR9709196A (pt) | 1999-05-25 |
MA26426A1 (fr) | 2004-12-20 |
CA2252696A1 (en) | 1997-11-06 |
CZ341098A3 (cs) | 1999-03-17 |
NO984939L (no) | 1998-12-23 |
HUP9901359A3 (en) | 2000-03-28 |
HUP9901359A2 (hu) | 1999-08-30 |
EP0915843A1 (en) | 1999-05-19 |
JP2000509049A (ja) | 2000-07-18 |
ID16660A (id) | 1997-10-30 |
NZ332476A (en) | 2000-06-23 |
NO984939D0 (no) | 1998-10-23 |
AU2698697A (en) | 1997-11-19 |
AR006833A1 (es) | 1999-09-29 |
TR199802160T2 (xx) | 1999-04-21 |
WO1997041098A1 (en) | 1997-11-06 |
PL329530A1 (en) | 1999-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA959100B (en) | Azetidinone derivatives for the treatment of atherosclerosis | |
AU4389896A (en) | Substituted azetidin-2-ones for treatment of atherosclerosis | |
PL329875A1 (en) | Derivatives of carbolin | |
PL329195A1 (en) | Derivatives of 6-phenylpyridol-2-amine | |
AP9701161A0 (en) | Azetidinone derivatives for the treatment of atherosclerosis | |
IL126696A0 (en) | Azetidinone derivatives for the treatment of atherosclerosis | |
HU9702042D0 (en) | Atherosclerosis treatment | |
IL122555A0 (en) | Water-stabilized organosilane compounds and methods for using the same | |
AUPP069497A0 (en) | Curtain assembly for waste treatment | |
GB9619492D0 (en) | Novel treatment | |
HUP0002709A3 (en) | Process for the reduction of 1-substituted -3-hydroxymethyl-4- (4-fluorophenyl)tetrahydropyridines | |
GB9615767D0 (en) | Novel treatment | |
GB9608657D0 (en) | Novel treatment | |
ZA981731B (en) | Use of a 7alpha-methyl-17alpha-ethynyl-estrane derivative for the treatment of atherosclerosis | |
GB9612752D0 (en) | Novel treatment | |
SI0914321T1 (en) | Indole derivatives for the treatment of osteoporosis | |
ZA968320B (en) | Treatment of atherosclerosis | |
GB9617762D0 (en) | Treatment | |
MD862F1 (en) | Remedy for dislipidemy and atherosclerosis treatment | |
GB9620687D0 (en) | Nebuliser | |
GB9606130D0 (en) | Nebuliser | |
AU4771096A (en) | Treatment for hypercholesterolemia | |
GB9616409D0 (en) | Novel treatment | |
GB9625201D0 (en) | Novel treatment | |
GB9616415D0 (en) | Novel treatment |